Vineet Agarwal
Keine laufenden Positionen mehr
Vermögen: - $ am 31.05.2024
Profil
Vineet Agarwal is currently the Chief Financial Officer at Korro Bio, Inc. (United States) since 2021.
He is also the Treasurer, Chief Financial & Accounting Officer at Korro Bio, Inc. since 2023.
Previously, he worked as the Executive Director-Biotech Investment Banking at 09143628 Ltd.
from 2019 to 2021.
He also held the position of Executive Director at JPMorgan Chase & Co. from 2019 to 2021.
Mr. Agarwal holds an MBA from the Institute of Management Technology and an undergraduate degree from Shri Ram College of Commerce.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
-.--% | 17.04.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Vineet Agarwal
| Unternehmen | Position | Beginn |
|---|---|---|
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Finanzdirektor/CFO | 01.05.2021 |
Ehemalige bekannte Positionen von Vineet Agarwal
| Unternehmen | Position | Ende |
|---|---|---|
| 09143628 Ltd. | Corporate Officer/Principal | 01.05.2021 |
| JPMORGAN CHASE & CO. | Direktor/Vorstandsmitglied | 01.05.2021 |
Ausbildung von Vineet Agarwal
| Institute of Management Technology | Masters Business Admin |
| Shri Ram College of Commerce | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JPMORGAN CHASE & CO. | Finance |
| Private Unternehmen | 2 |
|---|---|
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
| 09143628 Ltd. | Finance |
